Trial Profile
A Randomized, Phase 2/3, Open-Label, Multi-center Study of the Pharmacokinetics, Pharmacodynamics, Safety and Efficacy of A Long-acting Human Growth Hormone (Somavaratan, VRS-317) in Pre-pubertal Japanese Children With Growth Hormone Deficiency (GHD)
Status:
Discontinued
Phase of Trial:
Phase II/III
Latest Information Update: 27 Jul 2022
Price :
$35
*
At a glance
- Drugs Somavaratan (Primary)
- Indications Growth disorders; Somatotropin deficiency
- Focus Registrational; Therapeutic Use
- Sponsors Versartis
- 26 Oct 2017 Status changed from recruiting to discontinued, according to a Versartis media release.
- 27 Apr 2017 According to a Versartis media release, the company anticipates to complete enrollment in the phase III portion of the trial in the second half of 2017.
- 04 Apr 2017 Results (n=48) comapring PK/PD properties of somavaratan in USA and Japan prepubertal children using patient data from VERTICAL and J14VR5 trials, presented at The 99th Annual Meeting of the Endocrine Society